Cardiology Group pays $2 million to settle bogus claims

Published Date: 02 Mar 2023

Florida Cardiology PA and 10 cardiologists have filed a bogus lawsuit and must pay $2 million to settle the lawsuit outside the United States and will still “deny” wrongdoing.

Read Full News

Todays Updates


Interpreting the DAWN Trial: Where Anti-CD38 Therapy May Fit in NMOSD Care Marco Meglio


Neurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.

ISC 2026 Stroke Updates: Extended Time Windows and Secondary Prevention Strategies Ava L. Liberman, MD, Isabella Ciccone, MPH


Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.

American College of Physicians Policy Paper Recommends Retiring 'Provider' Term for Physicians Isabella Ciccone, MPH


ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

CD-38 Monoclonal Antibody Daratumumab Shows Promise as Treatment for NMOSD in Phase 3 DAWN Study Marco Meglio


Phase 3 DAWN data show daratumumab cuts NMOSD relapse risk 76%, stays well tolerated, and may improve disability, signaling a new targeted option.

Tips on Billing Issues in Dermatology Practices, With Daniel Siegel, MD Daniel M. Siegel, MD


Siegel addressed additional points presented in his Maui Derm 2026 session, 'How To Maximize Your Billing Effectiveness in the Era of Dwindling Reimbursements and ICD-10.'

7 Pulmonology Headlines You Missed in January 2026


7 Pulmonology Headlines You Missed in January 2026

Todays Updates


Interpreting the DAWN Trial: Where Anti-CD38 Therapy May Fit in NMOSD Care Marco Meglio


Neurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.

ISC 2026 Stroke Updates: Extended Time Windows and Secondary Prevention Strategies Ava L. Liberman, MD, Isabella Ciccone, MPH


Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.

American College of Physicians Policy Paper Recommends Retiring 'Provider' Term for Physicians Isabella Ciccone, MPH


ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

CD-38 Monoclonal Antibody Daratumumab Shows Promise as Treatment for NMOSD in Phase 3 DAWN Study Marco Meglio


Phase 3 DAWN data show daratumumab cuts NMOSD relapse risk 76%, stays well tolerated, and may improve disability, signaling a new targeted option.

Tips on Billing Issues in Dermatology Practices, With Daniel Siegel, MD Daniel M. Siegel, MD


Siegel addressed additional points presented in his Maui Derm 2026 session, 'How To Maximize Your Billing Effectiveness in the Era of Dwindling Reimbursements and ICD-10.'

7 Pulmonology Headlines You Missed in January 2026


7 Pulmonology Headlines You Missed in January 2026

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Potential new therapy for childhood brain cancer could heal treatment-resistant tumors

2.

The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

3.

What is Mohs micrographic surgery? 8 FAQs about Mohs

4.

Atezolizumab Consolidation Impresses in High-Risk DLBCL

5.

The risk of cancer is decreased by following international health recommendations.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot